Latest Ratios: P/E Ratio -4.2x · EV/EBITDA N/A · ROE -36.0%. (2016–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $146M | $202M | $225M | $7M | $13M | $27M | $69M | — | — | — | — |
| Enterprise Value | $6M | $62M | $169M | $-1770144 | $6M | $-13733704 | $56M | — | — | — | — |
| P/E Ratio → | -4.18 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | 26.00 | 102.12 | 8.63 | 99.29 | — | — | — | — |
| P/B Ratio | 1.17 | 1.17 | 2.38 | 0.62 | 0.60 | 0.70 | 7.09 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | -6.80 | 46.73 | -4.43 | 79.77 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | -5127.8% | 94.6% | -266.4% | -28.0% | -127.4% | 9.7% | 14.8% | 12.5% |
| Operating Margin | — | — | — | -7712.0% | -14686.2% | -476.2% | -403.5% | -507.5% | -52.5% | -19.7% | -63.4% |
| Net Profit Margin | — | — | — | -7304.8% | -14625.9% | -476.9% | -407.7% | -509.7% | -53.3% | -21.2% | -65.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -36.0% | -36.0% | -52.0% | -118.9% | -60.7% | -61.4% | -107.6% | — | — | — | — |
| ROA | -34.5% | -34.5% | -48.7% | -96.5% | -53.6% | -51.7% | -38.4% | -396.8% | -137.5% | -194.6% | -385.9% |
| ROIC | -108.0% | -108.0% | -104.8% | -181.2% | -224.5% | — | — | — | — | — | — |
| ROCE | -38.8% | -38.8% | -54.0% | -124.4% | -60.8% | -60.9% | -96.4% | — | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.00 | 0.06 | 0.02 | 0.01 | 0.03 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.81 | -0.59 | -0.78 | -0.33 | -1.05 | -1.39 | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | -0.20 | — | — |
| Interest Coverage | — | — | — | — | -242.49 | -741.16 | -95.86 | -229.44 | -69.96 | — | — |
Net cash position: cash ($139M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 21.70 | 21.70 | 26.37 | 4.13 | 6.59 | 10.47 | 3.13 | 0.01 | 0.35 | 0.11 | 0.05 |
| Quick Ratio | 21.70 | 21.70 | 26.37 | 4.13 | 6.59 | 10.47 | 3.13 | 0.01 | 0.35 | 0.11 | 0.05 |
| Cash Ratio | 21.54 | 21.54 | 26.13 | 3.85 | 6.24 | 10.05 | 2.96 | 0.00 | 0.10 | 0.01 | 0.01 |
| Asset Turnover | — | — | — | 0.02 | 0.00 | 0.07 | 0.05 | 29.35 | 1.42 | 7.23 | 5.94 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | 999999.00 |
| Days Sales Outstanding | — | — | — | — | 117.92 | 12.97 | — | — | 42.72 | 32.02 | 25.23 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $98M | $69M | $5M | $4M | $3M | $2M | $2M | $1M | $2M | $1M |
Clinical trial execution failure
As reported in financial statements, IKT's price-to-book ratio of 1.09 suggests that the market is assigning minimal value to the company's intellectual property and RAMP platform, effectively pricing the firm near its liquidation value rather than its potential as a clinical-stage neurodegeneration developer.
The current valuation appears to reflect a significant discount compared to peers like Denali Therapeutics, likely due to the absence of commercial revenue and the binary nature of upcoming clinical readouts. Investors should monitor whether this valuation floor holds as the company approaches critical Phase 2 data milestones, which may serve as the primary catalyst for a re-rating.
Based on IKT's reported figures, the ROIC has remained deeply negative, fluctuating between -18.0% and -110.4% over the last ten quarters, which is characteristic of a firm prioritizing long-term R&D investment over immediate capital efficiency or the generation of positive returns on invested capital.
The persistent decay in ROIC is an expected outcome of the company's current business model, where capital is consumed to fund clinical trials rather than to generate operating income. Analysts should interpret these negative returns not as a failure of capital allocation, but as a necessary cost of advancing the pipeline toward potential regulatory approval.
According to recent SEC filings, IKT maintains a current ratio of 30.14 as of 2026Q1, indicating a robust liquidity position that provides a substantial buffer against the company's ongoing cash burn and ensures operational continuity through the next several quarters of clinical trial activity.
This high liquidity ratio is a critical differentiator for IKT, as it mitigates the immediate risk of dilutive financing in a volatile biotech funding environment. While this provides a safety net, investors should monitor the rate of cash depletion to ensure that the current runway remains sufficient to reach the next major clinical data readout.
As evidenced by peer comparison data, IKT's valuation multiples remain compressed relative to larger neurodegeneration players like ACADIA Pharmaceuticals, suggesting that the market is applying a significant risk premium to IKT's earlier-stage pipeline and lack of established commercial partnerships compared to its industry counterparts.
The gap in valuation appears structural, reflecting the difference between IKT's clinical-stage status and the more advanced, revenue-generating profiles of its peers. This discrepancy warrants further investigation into whether the market is underestimating the potential of the RAMP platform or correctly pricing the inherent risks of the company's specific therapeutic focus.
Based on an analysis of the company's financial structure, the use of P/E ratios is fundamentally misapplied to IKT, as the firm's pre-revenue status renders earnings-based valuation metrics entirely irrelevant and potentially misleading for investors attempting to gauge the company's true intrinsic value.
Investors should instead focus on metrics such as cash runway, clinical trial enrollment velocity, and the probability-adjusted net present value of the pipeline. Relying on traditional profitability ratios obscures the reality that IKT's value is derived from future clinical success rather than current operational performance or historical earnings.
Includes 30+ ratios · 10 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying IKT stock.
Inhibikase Therapeutics, Inc.'s current P/E ratio is -4.2x. This places it at the 50th percentile of its historical range.
Inhibikase Therapeutics, Inc.'s return on equity (ROE) is -36.0%. The historical average is -72.8%.
Based on historical data, Inhibikase Therapeutics, Inc. is trading at a P/E of -4.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.